


Day 2

Sunday, 6th September 2015

TIME	TOPIC	CHAIRPERSON / SPEAKER
0900 - 0910	Welcome and introductions	<i>Prof Veera Sekaran</i>
0910 - 0945	Presentation: Clinical relevance of achieving molecular response <ul style="list-style-type: none"> • ELN recommendations for timing and frequency of monitoring • Impact of early and deep responses on clinical outcomes 	<i>Dr. Giuseppe Saglio</i>
0945 - 1015	Presentation: Current approaches and challenges to BCR-ABL testing <ul style="list-style-type: none"> • Standardization of molecular monitoring using the IS • Standardized reference reagents and sample exchange 	<i>Dr. Susan Branford</i>
1015 - 1030	BREAK	
1030 - 1145	Presentation and discussion: Importance of standardized reports for monitoring CML <ul style="list-style-type: none"> • Review the key elements of BCR-ABL reports • Discuss how the information is used in disease management • Review example report formats • Discuss the benefits of standardized reporting (ideal report format) 	<i>Dr. Giuseppe Saglio</i> <i>Dr. Susan Branford</i>
1145 - 1245	Best practices discussion: Overcoming obstacles to molecular monitoring on the IS <ul style="list-style-type: none"> • Discussion of local barriers to monitoring on IS (e.g., access, irregular frequency, etc.) • Best practices and tactics that can be implemented locally to overcome barriers • Question and answer session 	<i>Dr. Susan Branford</i> <i>Group discussion</i>
1245 - 1300	Concluding remarks	<i>Prof Veera Sekaran</i>



An educational event organized by:




Supported by:




RSVP: Please complete the registration form and send by fax to **Ms Jrence Chua @ +603 9171 8177** or via **e-mail: jrence@micepodium.com**
 For further enquiries, please contact **Ms Jrence @ +603 9171 8188**

TAS-INV.01.1508367554



INVITATION



HAEMATOLOGY UPDATES 2015

5th - 6th September 2015
Connexion@Nexus, Bangsar South, KL

Day 1

Saturday, 5th September 2015

TIME	TOPIC	CHAIRPERSON / SPEAKER
0800 - 0830	Registration	
0830 - 0840	Welcome Address	<i>Dr Alan Teh</i>
	CML/MPN Panel	<i>Dr Ng Soo Chin</i>
0840 - 0910	Clinico-Pathology Diagnostic Challenges in MPN	<i>Prof Wong Chieh Lee</i>
0910 - 0940	Paradigm Shift in the Management of MF	<i>Dr Haifa Kathrin Al Ali</i>
0940 - 0950	MF Case Review	<i>Dr Haifa Kathrin Al Ali</i>
0950 - 1005	MF Case Discussion	<i>Dr Tan Jenq Tzong</i>
1005 - 1020	MF Case Discussion	<i>Dr Teoh Ching Soon</i>
1020 - 1035	TEA BREAK	
1035 - 1045	E-voting	
1045 - 1130	Optimizing Outcomes in Patients with CML	<i>Dr Giuseppe Saglio</i>
1130 - 1205	Monitoring & responding: a chronic disease with acute opportunities	<i>Dr Susan Branford</i>
1205 - 1220	CML Case Discussion	<i>Dr Sharifah Suryani</i>
	Bleeding Disorder Panel	<i>Dr Goh Ai Sim</i>
1220 - 1300	"Extending experience in the management of ITP: what's changed over the last decade?"	<i>Dr Gregory Cheng</i>
1300 - 1315	ITP case discussion	<i>Dr Nur Adila Anuar</i>
1315 - 1400	LUNCH	
	Myeloma/MDS Panel	<i>Prof Gan Gin Gin</i>
1400 - 1430	Updates on the Management of Multiple Myeloma	<i>Dr Lim Su Hong</i>
1430 - 1445	MM Case Discussion	<i>Dr Mandy Yap</i>
1445 - 1515	Myelodysplastic Syndrome (MDS) - What's new?	<i>Dr Liew Hong Keng</i>
1515 - 1530	MDS Case Discussion	<i>Dr Ernie Yap</i>
1530 - 1545	TEA BREAK	
	Lymphomas Panel	<i>Dr Alan Teh</i>
1545 - 1615	Updates on Management of Hodgkin's Lymphoma (HL)	<i>Dr Chew Lee Ping</i>
1615 - 1630	HL Case Discussion	<i>Dr Lee Bee Sun</i>
1630 - 1700	Non-Hodgkin's lymphoma (NHL) - Double Hit Lymphomas: time for a targeted approach	<i>Dr Lau Ngee Siang</i>
1700 - 1715	NHL Case Discussion	<i>Dr Wong Chin Hau</i>
1715 - 1720	CLOSING REMARKS	<i>Dr Alan Teh</i>



DR HAIFA KATHRIN AL-ALI

University Hospital of Leipzig
Leipzig, Germany

Dr Haifa Kathrin Al-Ali is a Senior Consultant in the Department of Haematology and Medical Oncology at the University Hospital of Leipzig, Germany.

Dr Al-Ali trained at Baghdad University, Iraq, where she obtained her first degree in Medicine and Surgery in 1987, and a doctoral degree in Internal Medicine in 1995. Since 1999, Dr. Al-Ali works in the Department of Haematology and Medical Oncology at the University Hospital of Leipzig, Germany. After her specialisation in haematology, she took up her current post as a Senior Consultant in 2005.

The main clinical interest of Dr Al-Ali is myeloid malignancies (MPN, AML, MDS) and allogeneic haematopoietic cell transplantation. She has an extensive publication history, with articles published in such prestigious journals as The New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Leukemia. She has also presented abstracts at many international congresses, including meetings of the American Society of Hematology (ASH), the European Hematology Association (EHA) and the European Group for Blood and Marrow Transplantation (EBMT).



DR GIUSEPPE SAGLIO

MD, University of Turin, Italy

Dr. Giuseppe Saglio is Professor of Internal Medicine and Haematology at the University of Turin. He is Director of the Department of Molecular Medicine and Targeted Therapy and responsible for the Division of Internal Medicine and Haematology at San Luigi Hospital (University of Turin). He graduated from the University of Turin in 1975. Since then he has studied Internal Medicine at the University of Turin (1975-1980), Haematology at the University of Milan (1980-1983) and Molecular Biology at the University of Leiden (1976), Inserm-Creteil, Paris (1979) and the University of California (1983).

Dr. Saglio is co-ordinator of the PhD programme in molecular medicine at the University of Turin, past-president of the Italian Society of Experimental Haematology (SIES) and is a member of the Academy of Medicine of Turin. He has published more than 350 peer-reviewed articles in the fields of molecular pathogenesis of haematological malignancies (1986-present), molecular medicine applied to clinical medicine (1978-1990) and the molecular basis of thalassemia and related haemoglobinopathies (1978-1990).

INVITED SPEAKERS



DR SUSAN BRANFORD

PhD,
School of Medicine, Adelaide University, Adelaide, Australia

Dr Susan Branford holds the position of an Associate Professor at the School of Medicine and the School of Molecular and Biomedical Science of Adelaide University in Australia. She has special expertise in molecular monitoring of the BCR ABL gene for patients with chronic myeloid leukaemia. As such she is a major contributor to international collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data.

Dr Branford's main research is focused on the formation of the BCR ABL gene, the mechanisms of kinase inhibitor drug resistance and the factors that predict for response to therapy and the development of drug resistance.



DR GREGORY CHENG

MD, PhD
Macau University of Science & Technology Hospital, Macau

Dr. Gregory Cheng, MD, PhD is Consultant Hematologist at the Macau University of Science & Technology Hospital, Macau. He earned his medical degree and PhD degree from the University of Toronto in 1978 and 1989 respectively. His clinical practice and research focus on immune thrombocytopenia, deep vein thrombosis, transfusion medicine and hematologic malignancies, such as acute and chronic leukemia, myelodysplastic syndromes, myeloproliferative disorders, lymphomas, and myeloma.

During recent years, Dr. Cheng's Hematology department has been involved in phase I-III studies of several ground-breaking, new therapeutic approaches. These include, but are not limited to, pulsed dexamethasone and eltrombopag in idiopathic thrombocytopenic purpura (ITP), bosutinib in chronic myeloid leukemia, vorinostat in myeloma, apixaban in DVT prophylaxis, FIXFc in hemophilia B. His research has resulted in publications in peer-reviewed journals such as the New England Journal of Medicine, Lancet, JAMA, Blood, and BMJ etc.